Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Rezolute, a late-stage biopharmaceutical company specializing in therapies for rare diseases, announced a proposed public offering of its common stock and pre-funded warrants. The company aims to grant underwriters a 30-day option to purchase an additional 15% of shares. This offering is subject to market conditions, and Jefferies and Cantor are managing the process. A shelf registration statement was filed with the SEC and declared effective on November 29, 2023. Copies of the prospectus supplement and accompanying prospectus will be available via the SEC's website and through Jefferies and Cantor Fitzgerald & Co.
- Rezolute is initiating a public offering to raise capital, potentially strengthening its financial position.
- The underwriters have the option to purchase an additional 15% of shares, which could increase total funds raised.
- The SEC has already declared effective the shelf registration statement related to the offering, ensuring regulatory compliance.
- The public offering might dilute the value of existing shares, affecting current shareholders.
- The offering's success is uncertain and dependent on market conditions, posing a risk to planned capital raising.
- Rezolute's reliance on this offering may indicate underlying financial needs or challenges.
Insights
The announcement of a public offering of common stock and pre-funded warrants by Rezolute, Inc. indicates a strategic move to raise capital. This decision has several significant implications for stakeholders. Firstly, the influx of funds can provide much-needed liquidity to continue their research and development, especially considering they are a late-stage biopharmaceutical company focusing on rare diseases.
However, issuing a large number of shares or warrants might lead to dilution of existing shareholders' equity, potentially lowering the stock price in the short term. Investors should consider how the raised capital will be utilized; if effectively invested, it could lead to long-term gains through successful product development and commercialization.
Rezolute's decision to proceed with a public offering underlines their confidence in the market's reception of their upcoming products. The involvement of prominent financial institutions like Jefferies and Cantor as book-running managers adds credibility to the offering and can boost investor confidence.
However, the timing and size of the offering will be critical. Given the market conditions mentioned, there's uncertainty regarding the completion and terms of the offering. Investors will need to monitor market sentiment closely. Moreover, the success of their key product, RZ358, in treating hyperinsulinism could be a pivotal factor in how the market views this offering.
NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare diseases, today announced that it is commencing an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase its common stock in lieu thereof). In addition, the Company intends to grant the underwriters an option for a period of 30 days to purchase up to an additional 15 percent of the number of shares of its common stock plus the shares of common stock underlying pre-funded warrants sold in connection with the public offering. The public offering is subject to market and other conditions, and there can be no assurance as to whether or when the public offering may be completed or as to the actual size or terms of the public offering. All of the shares in the public offering are being offered by the Company.
Jefferies and Cantor are acting as the book-running managers for the public offering.
A shelf registration statement on Form S-3 (File No. 333-275562) relating to the securities to be offered in the public offering was filed with the Securities and Exchange Commission (the “SEC”) and was declared effective on November 29, 2023. The public offering will be made only by means of a prospectus supplement and accompanying prospectus that form a part of the registration statement. A preliminary prospectus supplement related to the public offering will be filed with the SEC and, when available, may be obtained on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and accompanying prospectus relating to the public offering, when available, may be obtained by contacting: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at 877-821-7388, or by email at prospectus_department@jefferies.com or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com
This press release does not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, RZ358, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital hyperinsulinism and tumor hyperinsulinism.
Forward-Looking Statements
Any statements in this press release about the Company’s future expectations, plans and prospects, including statements regarding the proposed public offering, constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Forward-looking statements include any statements about the Company’s strategy, future operations and future expectations and plans and prospects for the Company, and any other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions. Such forward-looking statements involve substantial risks and uncertainties that could cause the Company’s development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, those related to market and other financial conditions, the potential completion of the proposed public offering or the size or terms thereof, satisfaction of customary closing conditions related to the proposed public offering and other factors discussed in the “Risk Factors” section contained in the preliminary prospectus supplement and the reports that the Company files with the SEC. Any forward-looking statements represent the Company’s views only as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. While the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so except as required by law.
Contacts:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614
FAQ
What is Rezolute's stock symbol?
What did Rezolute announce on June 13, 2024?
Who are the managers for Rezolute's public offering?
What is the purpose of Rezolute's public offering?
When was the shelf registration statement declared effective by the SEC?
